[go: up one dir, main page]

EA201790239A1 - Молекула-носитель для антигенов - Google Patents

Молекула-носитель для антигенов

Info

Publication number
EA201790239A1
EA201790239A1 EA201790239A EA201790239A EA201790239A1 EA 201790239 A1 EA201790239 A1 EA 201790239A1 EA 201790239 A EA201790239 A EA 201790239A EA 201790239 A EA201790239 A EA 201790239A EA 201790239 A1 EA201790239 A1 EA 201790239A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugate
antigens
antigen
spb1
mammal
Prior art date
Application number
EA201790239A
Other languages
English (en)
Inventor
Франческо Берти
Роберта Коцци
Гвидо Гранди
Доменико Майоне
Иммакулада Маргарит И Рос
Чира Даньела Ринаудо
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201790239A1 publication Critical patent/EA201790239A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В изобретении предложен конъюгат, содержащий антиген и молекулу-носитель, где указанная молекула-носитель содержит антиген ВР-2а и антиген spb1. BP-2a и spb1 представляют собой антигены Streptococcus agalactiae.Конъюгат может найти применение в способе индуцирования иммунного ответа у млекопитающего, включающем введение данного конъюгата млекопитающему. Также предложены фармацевтические композиции, в частности вакцины, содержащие конъюгат.
EA201790239A 2014-08-05 2015-08-05 Молекула-носитель для антигенов EA201790239A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179945 2014-08-05
PCT/EP2015/068012 WO2016020413A1 (en) 2014-08-05 2015-08-05 Carrier molecule for antigens

Publications (1)

Publication Number Publication Date
EA201790239A1 true EA201790239A1 (ru) 2017-07-31

Family

ID=51298571

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790239A EA201790239A1 (ru) 2014-08-05 2015-08-05 Молекула-носитель для антигенов

Country Status (16)

Country Link
US (1) US10245310B2 (ru)
EP (1) EP3177324A1 (ru)
JP (1) JP2017523985A (ru)
KR (1) KR20170039709A (ru)
CN (1) CN108064174A (ru)
AR (1) AR101455A1 (ru)
AU (1) AU2015299008B2 (ru)
BE (1) BE1022792B1 (ru)
BR (1) BR112017002183A2 (ru)
CA (1) CA2957118A1 (ru)
EA (1) EA201790239A1 (ru)
IL (1) IL250238A0 (ru)
MX (1) MX2017001638A (ru)
SG (1) SG11201700673RA (ru)
WO (1) WO2016020413A1 (ru)
ZA (1) ZA201700824B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2662651T3 (es) * 2005-06-27 2018-04-09 Glaxosmithkline Biologicals S.A. Composición inmunógena
EP3551668A1 (en) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Purification process for capsular polysaccharide
AU2017388891C1 (en) 2016-12-30 2025-04-17 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
WO2019217665A1 (en) * 2018-05-09 2019-11-14 West Virginia University Iron-acquisition receptor peptide administration for vaccination against pseudomonas aeruginosa
WO2020010000A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
MX2020014118A (es) * 2018-07-04 2021-06-18 Vaxcyte Inc Mejoras en conjugados inmunogenicos.
CN108840914B (zh) * 2018-08-13 2022-07-01 内蒙古民族大学 一种具有免疫原性的多肽、其抗体的制备方法以及用途
KR20210146392A (ko) 2019-04-02 2021-12-03 박사이트, 인코포레이티드 침습 플라스미드 항원 b의 최적화된 무세포 합성 및 관련 조성물 및 사용 방법
CN114728051A (zh) 2019-11-22 2022-07-08 葛兰素史克生物有限公司 细菌糖糖缀合物疫苗的剂量和施用
EP4165064A2 (en) * 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system
US20230303637A1 (en) 2020-06-12 2023-09-28 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
CN112979797B (zh) * 2021-04-28 2022-04-01 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体及其制备方法与应用
GB202215634D0 (en) * 2022-10-21 2022-12-07 Glaxosmithkline Biologicals Sa Polypeptide scaffold

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2006069200A2 (en) 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
EP2063911A2 (en) * 2006-07-26 2009-06-03 Novartis Ag Immunogenic compositions for gram positive bacteria
GB0802503D0 (en) * 2008-02-11 2008-03-19 Novartis Ag Hybrid polypeptide
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) * 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP2015509713A (ja) 2012-02-24 2015-04-02 ノバルティス アーゲー 線毛タンパク質および組成物

Also Published As

Publication number Publication date
BR112017002183A2 (pt) 2018-01-16
WO2016020413A1 (en) 2016-02-11
EP3177324A1 (en) 2017-06-14
CA2957118A1 (en) 2016-02-11
ZA201700824B (en) 2019-07-31
SG11201700673RA (en) 2017-02-27
AU2015299008A1 (en) 2017-02-23
AR101455A1 (es) 2016-12-21
BE1022792B1 (fr) 2016-09-06
CN108064174A (zh) 2018-05-22
AU2015299008B2 (en) 2018-08-02
MX2017001638A (es) 2017-04-27
BE1022792A1 (fr) 2016-09-06
IL250238A0 (en) 2017-03-30
JP2017523985A (ja) 2017-08-24
US20170224803A1 (en) 2017-08-10
KR20170039709A (ko) 2017-04-11
US10245310B2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
EA201790239A1 (ru) Молекула-носитель для антигенов
MX395147B (es) Formulación de anticuerpo anti-cgrp.
MX381232B (es) Formulación de anticuerpos.
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CU20160101A7 (es) Inmunoglobulina con fab en tándem
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201590388A1 (ru) Способы лечения таупатии
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX384992B (es) Combinaciones inmunógenas.
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
UY37456A (es) Inmunoglobulinas y sus usos
EA201691348A1 (ru) Однофлаконные вакцинные составы
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
DK3661968T3 (da) Nanopartikelplatform til antistof- og vaccineindgivelse
EA201592203A1 (ru) Способы лечения таупатии
EA201891639A1 (ru) Аминокислотные и пептидные конъюгаты и способ конъюгации